Loading...
Loading...
ALBT| Name | Value |
|---|---|
| Revenues | 321.3K |
| Cost of Revenue | 271.0K |
| Gross Profit | 50.4K |
| Operating Expense | 899.5K |
| Operating I/L | -849.1K |
| Other Income/Expense | -8,706.0K |
| Interest Income | -402.5K |
| Pretax | -9,555.1K |
| Income Tax Expense | -0.0K |
| Net Income/Loss | -9,555.1K |
Avalon GloboCare Corp. operates commercial real estate properties in the US and China, offering medical consulting services, research studies, and management services in immunotherapy and second opinion/referral services. Its leading candidates include AVA-001, an anti-CD19 CAR-T, and AVA-011, a pre-clinical stage RNA-based FASH-CARTM cell therapy platform. The company also develops avalon clinical-grade tissue-specific exosome (ACTEX) and therapeutic and diagnostic targets utilizing QTY-code protein design technology with MIT. Additionally, it has a strategic partnership with the University of Natural Resources and Life Sciences in Vienna to develop an S-layer vaccine against SARS-CoV-2. Avalon GloboCare Corp. also promotes standardization related to the exosome industry.
